Cargando…

Hospitalizations and Treatment Outcomes in Patients with Urogenital Tuberculosis in Tashkent, Uzbekistan, 2016–2018

Despite the global shift to ambulatory tuberculosis (TB) care, hospitalizations remain common in Uzbekistan. This study examined the duration and determinants of hospitalizations among adult patients (≥18 years) with urogenital TB (UGTB) treated with first-line anti-TB drugs during 2016–2018 in Tash...

Descripción completa

Detalles Bibliográficos
Autores principales: Ismatov, Bakhtiyor, Sereda, Yuliia, Sahakyan, Serine, Gadoev, Jamshid, Parpieva, Nargiza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124920/
https://www.ncbi.nlm.nih.gov/pubmed/33946457
http://dx.doi.org/10.3390/ijerph18094817
_version_ 1783693349334548480
author Ismatov, Bakhtiyor
Sereda, Yuliia
Sahakyan, Serine
Gadoev, Jamshid
Parpieva, Nargiza
author_facet Ismatov, Bakhtiyor
Sereda, Yuliia
Sahakyan, Serine
Gadoev, Jamshid
Parpieva, Nargiza
author_sort Ismatov, Bakhtiyor
collection PubMed
description Despite the global shift to ambulatory tuberculosis (TB) care, hospitalizations remain common in Uzbekistan. This study examined the duration and determinants of hospitalizations among adult patients (≥18 years) with urogenital TB (UGTB) treated with first-line anti-TB drugs during 2016–2018 in Tashkent, Uzbekistan. This was a cohort study based on the analysis of health records. Of 142 included patients, 77 (54%) were males, the mean (±standard deviation) age was 40 ± 16 years, and 68 (48%) were laboratory-confirmed. A total of 136 (96%) patients were hospitalized during the intensive phase, and 12 (8%) had hospital admissions during the continuation phase of treatment. The median length of stay (LOS) during treatment was 56 days (Interquartile range: 56–58 days). LOS was associated with history of migration (adjusted incidence rate ratio (aIRR): 0.46, 95% confidence interval (CI): 0.32–0.69, p < 0.001); UGTB-related surgery (aIRR: 1.18, 95% CI: 1.01–1.38, p = 0.045); and hepatitis B comorbidity (aIRR: 3.18, 95% CI: 1.98–5.39, p < 0.001). The treatment success was 94% and it was not associated with the LOS. Hospitalization was almost universal among patients with UGTB in Uzbekistan. Future research should focus on finding out what proportion of hospitalizations were not clinically justified and could have been avoided.
format Online
Article
Text
id pubmed-8124920
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81249202021-05-17 Hospitalizations and Treatment Outcomes in Patients with Urogenital Tuberculosis in Tashkent, Uzbekistan, 2016–2018 Ismatov, Bakhtiyor Sereda, Yuliia Sahakyan, Serine Gadoev, Jamshid Parpieva, Nargiza Int J Environ Res Public Health Article Despite the global shift to ambulatory tuberculosis (TB) care, hospitalizations remain common in Uzbekistan. This study examined the duration and determinants of hospitalizations among adult patients (≥18 years) with urogenital TB (UGTB) treated with first-line anti-TB drugs during 2016–2018 in Tashkent, Uzbekistan. This was a cohort study based on the analysis of health records. Of 142 included patients, 77 (54%) were males, the mean (±standard deviation) age was 40 ± 16 years, and 68 (48%) were laboratory-confirmed. A total of 136 (96%) patients were hospitalized during the intensive phase, and 12 (8%) had hospital admissions during the continuation phase of treatment. The median length of stay (LOS) during treatment was 56 days (Interquartile range: 56–58 days). LOS was associated with history of migration (adjusted incidence rate ratio (aIRR): 0.46, 95% confidence interval (CI): 0.32–0.69, p < 0.001); UGTB-related surgery (aIRR: 1.18, 95% CI: 1.01–1.38, p = 0.045); and hepatitis B comorbidity (aIRR: 3.18, 95% CI: 1.98–5.39, p < 0.001). The treatment success was 94% and it was not associated with the LOS. Hospitalization was almost universal among patients with UGTB in Uzbekistan. Future research should focus on finding out what proportion of hospitalizations were not clinically justified and could have been avoided. MDPI 2021-04-30 /pmc/articles/PMC8124920/ /pubmed/33946457 http://dx.doi.org/10.3390/ijerph18094817 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ismatov, Bakhtiyor
Sereda, Yuliia
Sahakyan, Serine
Gadoev, Jamshid
Parpieva, Nargiza
Hospitalizations and Treatment Outcomes in Patients with Urogenital Tuberculosis in Tashkent, Uzbekistan, 2016–2018
title Hospitalizations and Treatment Outcomes in Patients with Urogenital Tuberculosis in Tashkent, Uzbekistan, 2016–2018
title_full Hospitalizations and Treatment Outcomes in Patients with Urogenital Tuberculosis in Tashkent, Uzbekistan, 2016–2018
title_fullStr Hospitalizations and Treatment Outcomes in Patients with Urogenital Tuberculosis in Tashkent, Uzbekistan, 2016–2018
title_full_unstemmed Hospitalizations and Treatment Outcomes in Patients with Urogenital Tuberculosis in Tashkent, Uzbekistan, 2016–2018
title_short Hospitalizations and Treatment Outcomes in Patients with Urogenital Tuberculosis in Tashkent, Uzbekistan, 2016–2018
title_sort hospitalizations and treatment outcomes in patients with urogenital tuberculosis in tashkent, uzbekistan, 2016–2018
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124920/
https://www.ncbi.nlm.nih.gov/pubmed/33946457
http://dx.doi.org/10.3390/ijerph18094817
work_keys_str_mv AT ismatovbakhtiyor hospitalizationsandtreatmentoutcomesinpatientswithurogenitaltuberculosisintashkentuzbekistan20162018
AT seredayuliia hospitalizationsandtreatmentoutcomesinpatientswithurogenitaltuberculosisintashkentuzbekistan20162018
AT sahakyanserine hospitalizationsandtreatmentoutcomesinpatientswithurogenitaltuberculosisintashkentuzbekistan20162018
AT gadoevjamshid hospitalizationsandtreatmentoutcomesinpatientswithurogenitaltuberculosisintashkentuzbekistan20162018
AT parpievanargiza hospitalizationsandtreatmentoutcomesinpatientswithurogenitaltuberculosisintashkentuzbekistan20162018